Philips Places Simplicity at the Heart of Cardiac Care

Royal Philips ElectronicsSolutions offered by Philips can help to reduce the time from discovery of a heart attack to treatment to 90 minutes, the limit recommended by experts, by enabling hospitals to better organize resources throughout the treatment procedure, starting before patients enter their doors.

When a patient suffers a heart attack, heart muscle starts dying immediately. This means that every second saved between onset of chest pains and administration of treatment is vital. It is both proven and widely accepted that reducing the time from discovery to treatment, such as an emergency angioplasty procedure, in which a balloon is used to clear a blocked artery, has a significant impact on a patient's long-term recovery.* This has prompted the American College of Cardiology, in partnership with the American Heart Association and others around the world, to launch the 'Door to Balloon' (D2B) campaign to reduce the elapsed time from the arrival of the victim at the hospital to angioplasty to 90 minutes or less.

The Philips 'Discovery to Treatment' solution is a combination of products that help clinicians meet the 90 minute 'Door to Balloon' target. It means clinicians can make early assessments that would usually be made after arrival at the hospital to significantly speed up heart attack treatment and ensure patients are cared for more effectively right from the point their heart attack is discovered. The system allows paramedics to immediately transmit data from ambulance to hospital; in turn, clinicians in hospitals can receive ECG data and assess a patient’s condition and the type of treatment they will need before the patient even arrives at the emergency department.

As a patient moves through the cycle of cardiac care, whether in the ambulance, emergency department, diagnostic imaging center, catheterization (cath) lab, operating room and /or critical care ward, Philips helps to manage the flow of patient information, making it available when and where it is needed to enable health providers to offer better, faster care.

Philips' 'Discovery to Treatment' solution includes:

  • The HeartStart MRx monitor/defibrillator which enables paramedics to wirelessly transmit vital 12-lead electrocardiogram (ECG) patient data on the heart's condition while en route to the hospital
  • The Philips Tracemaster Vue system to manage the ECG data so that when the patient gets to the hospital, all usual administration is bypassed because details relating to them have been already received and entered in the system
  • The Xper FD10 imaging equipment in the cath lab which can be prepared in advance once the data is received, to help clinicians pinpoint issues in the heart and confidently plan and execute interventional procedures
  • The Philips Intellivue monitor which continually monitors the patient's vital signs and accompanies the patient through the hospital
  • The Philips CVIS informatics solution to ensure rapid access to the seamless sharing of clinical information at every stage of care in the hospital

"With over 17 million people around the world dying from cardiovascular disease each year, this is the world's number one cause of death," commented Joris van den Hurk, Vice President, Cardiology Care Cycles, Philips Healthcare. "That's why we're working together with cardiologists to develop technologies that integrate into each part of the cardiac care cycle - from emergency care to diagnosis, treatment and long-term care."

* De Luca G, Suryapranata H, Ottervanger JP, Antman EM., "Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts". Circulation, 2004 Mar 16; 109(10):1223-5. Selected quote: "These results suggest that every minute of delay in primary angioplasty for STEMI affects 1-year mortality, even after adjustment for baseline characteristics. Therefore, all efforts should be made to shorten the total ischemic time, not only for thrombolytic therapy but also for primary angioplasty."

Related news articles:

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified Health and Well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs approximately 128,000 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2007, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...